Genmab A/S
GMAB | NASDAQ
$34.69
-$0.05 (-0.14%)
At close: Sep 21, 2026, 4:00 PM ET
$34.34
-$0.35 (-1.01%)
Pre-market:
Sep 22, 2026, 4:01 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 3.72B | 21.53B | 16.47B | 14.51B | 8.42B | 10.11B |
Cost of Revenue | 309.24M | 985M | 226M | n/a | n/a | n/a |
Gross Profit | 3.41B | 20.54B | 16.25B | 14.51B | 8.42B | 10.11B |
Operating Income | 1.25B | 6.7B | 5.32B | 6.27B | 2.95B | 6.31B |
Interest Income | 138.11M | 995M | 939M | 324M | 197M | 184M |
Pretax Income | 1.2B | 9.16B | 5.64B | 6.95B | 3.92B | 5.9B |
Net Income | 963.76M | 7.84B | 4.35B | 5.45B | 2.96B | 4.76B |
Selling & General & Admin | 602.47M | 3.79B | 3.3B | 2.68B | 1.28B | 661M |
Research & Development | 1.56B | 9.75B | 7.63B | 5.56B | 4.18B | 3.14B |
Other Expenses | n/a | 300M | n/a | n/a | n/a | n/a |
Operating Expenses | 2.16B | 13.84B | 10.93B | 8.24B | 5.46B | 3.8B |
Interest Expense | 61.05M | 120M | 27M | 21M | 13M | 10M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.47B | 14.82B | 11.15B | 8.24B | 5.46B | 3.8B |
Income Tax Expense | 241.19M | 1.32B | 1.29B | 1.49B | 961M | 1.15B |
Shares Outstanding (Basic) | 621.51M | 646.34M | 659.19M | 653.87M | 653.96M | 651.79M |
Shares Outstanding (Diluted) | 626.92M | 646.33M | 659.15M | 660.1M | 660.46M | 658.86M |
EPS (Basic) | 1.55 | 12.14 | 6.60 | 8.34 | 4.52 | 7.30 |
EPS (Diluted) | 1.54 | 12.14 | 6.60 | 8.26 | 4.48 | 7.22 |
EBITDA | 1.34B | 9.7B | 5.95B | 7.35B | 4.18B | 6.16B |
EBIT | 1.27B | 9.28B | 5.71B | 6.97B | 3.93B | 5.91B |
Depreciation & Amortization | 71.06M | 413M | 240M | 362M | 250M | 246M |
Add to Watchlist
Select watchlists to add or remove GMAB